Development of a microfluidic platform for self-governing selection of individual B-cells using bioresponsive hydrogels: a source of fully human therapeutic antibodies KU Leuven
Monoclonal antibodies (mAb) are the biggest class of biopharmaceuticals used against cancer, inflammatory and autoimmune diseases. As the ability of the human immune system to generate highly specific mAb is unmatched by any man-made approach, several technologies have been developed to generate fully human (FH)-mAb. Among those, single B-cell screening has emerged as a powerful technique. In this project, two KU Leuven groups will join their ...